Atara Biotherapeutics, Inc. (ATRA) Stock AnalysisATRAAtara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Atara Biotherapeutics is currently priced at $9.20, with a forward P/E ratio of 3.63, suggesting it may be undervalued. However, the stock has seen a significant year-to-date decline of 48.23%, and insider selling has increased by 29504.54%, indicating potential risks. The recent upgrades from analysts suggest a cautious optimism, but the high insider selling and overall market sentiment lead to a recommendation to hold rather than buy.

6 analysts cover ATRA: 4 rate it Buy, 1 Hold and 1 Sell. The average price target is 21.50.